|
|
|
|
|
|
|
|
/ March 18–19 2020: World Pharma Pricing Market Access & Evidence Congress
/ |
|
Amsterdam, The Netherlands |
|
/ March 30–31, 2020: 6th Edition Drug Pricing Transparency Congress
/ |
|
Philadelphia, PA |
|
/ March 31–April 2, 2020: eyeforpharma Barcelona 2020
/ |
|
Barcelona, Spain |
|
/ April 20–22, 2020: Digital Health for Pharma
/ |
|
Philadelphia, PA. |
|
/ April 29–May 1, 2020: Pharmaceutical Compliance Congress (PCC) 2020
/ |
|
Washington, D.C. |
|
/ June 14–18, 2020: DIA 2020 Global Annual Meeting
/ |
|
Washington, D.C. |
 |
|
| |
|
|
|
|
| Industry update |
| //Genomics (Oxford, UK) appointed Mitchell Harris as Chief Strategy Officer and Professor Gil McVean as Chief Information Officer.
//
Cell line development instrumentation company Solentim (Bournemouth, UK) named Dr. Mark Truesdale as CEO.
//
Sutura Therapeutics (Birkenhead, UK) James Noble and Eduardo Bravo to its Board of Directors.
//
Summit (Oxford, UK, and Cambridge, MA) appointed Robert W. Duggan as Executive Chairman.
//
Enterprise Therapeutics (Brighton, UK) appointed Dr. David Morris M.D. as Chief Medical Officer.
//
Immuno-oncology company Nouscom (Basel, Switzerland) appointed Marina Udier, Ph.D., as CEO and Patricia Delaite, M.D. as Chief Medical Officer.
//
Helsinn (Lugano, Switzerland) named Eric Cornut and Lonnie Moulder as members of the Board of Directors of the Helsinn Group.
//
Affimed (Heidelberg, Germany) named Dr. Andreas Harstrick as Chief Medical Officer, effective March 2020.
|
|
|
|
|
|
|
|
|
|
|
